- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07636187
Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters (PROACTIVE)
A substantial portion of the United States population remains overdue for key screenings, despite availability and insurance coverage of preventive health services. Barriers for completion and remaining up to date with screening include patients not remaining actively engaged with their care team, time constraints during office visits, and operational strain. This project aims to implement and evaluate a primary care visit-based program that harmonizes multiple preventive health and chronic disease management care gaps, reduces staff burden, and improves ordering and subsequent patient follow through on completion of overdue care gaps.
In this study, the investigators will evaluate nudges to clinicians and patients to help increase screening completion for multiple care gaps identified as high priority by primary care, including imaging (Mammogram, DEXA) and labs (Diabetes Management (Hemoglobin A1C, Basic Metabolic Panel, and Urine Microalbumin), Hepatitis C, and Lipids). This will be a 6 month, stepped-wedge, pragmatic trial conducted at Penn Medicine.
Přehled studie
Postavení
Podmínky
Detailní popis
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- University of Pennsylvania Health System
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
All patients must meet the following criteria to be eligible:
- 18 years or older
- A scheduled new or return (non-urgent/sick) primary care visit at one of the study practices
- Overdue for at least one of the included care gaps according to Health Maintenance: Mammogram, DEXA, Hemoglobin A1C, Basic Metabolic Panel, Urine Microalbumin, Lipids, Hepatitis C
- Last eligible office visit was greater than or equal to 3 months ago
Exclusion Criteria:
As this trial is integrated with routine clinical operations, there will be no exclusion criteria. However, for each care gap independently, we will exclude all patient visits throughout the remaining trial duration after the patient's first eligible office visit within the trial duration. In other words, each patient will contribute data from at most one eligible office visit.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Control Condition
During the control condition, clinics will receive standard of care.
|
|
|
Experimentální: Active Intervention
During the active intervention, clinics will receive both clinician and patient facing nudges.
Patient nudges will be pre- and post-visit text message reminders about their overdue care gaps.
Clinician nudges will be default pended orders for overdue care gaps and an EHR Smart Data Element communication banner notifying the provider that a pre-visit reminder was sent to the patient and that orders have been pended for their review.
|
The patient nudges will be delivered by a series of one to three text messages.
Patients will receive the pre-visit text message 2 days prior to their scheduled primary care visit.
This message will remind them that they are overdue for their preventive care imaging and/or labs and encourage them to speak with their provider about screening completion during their upcoming appointment.
All patients who complete their primary care visit and whose provider signed at least one of their pended orders will be sent post-visit text messages 7 and 14 days after completion, if they have not yet scheduled or completed their overdue labs and/or imaging.
The messages delivered at 7 and 14 days will remind patients that appointments for lab and imaging are available for them and provide phone number(s) to call for scheduling and a link to complete scheduling online.
Patients will also have the option to engage with a bi-directional support menu via text message.
The default pended orders will be automatically placed into the patient's primary care visit encounter via a custom Epic extension for each included care gap (mammogram, DEXA, hemoglobin A1C, basic metabolic panel, urine microalbumin, lipids, and Hepatitis C) that the patient is overdue for according to their Health Maintenance status.
Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
An electronic health record (EHR) communication will be visible to the provider and entire care team during the visit encounter.
This smart data element (SDE) communication will display in the patient's EHR encounter as a section in pre-charting, check-in, and rooming, and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding their overdue status for their preventive care imaging and/or labs.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Mammogram Screening Completion (3 months)
Časové okno: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete a mammogram within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Hepatitis C Screening Completion (3 months)
Časové okno: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete Hepatitis C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
|
Lipids Screening Completion (3 months)
Časové okno: Within 3 months after first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 3 months after the first eligible primary care visit.
|
Within 3 months after first eligible primary care visit.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
DEXA Screening Completion (3 months)
Časové okno: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (3 months)
Časové okno: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (3 months)
Časové okno: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (3 months)
Časové okno: Within 3 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 3 months after the first eligible primary care visit.
|
Within 3 months after the first eligible primary care visit.
|
|
Mammogram Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete a mammogram within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hepatitis C Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hepatitis C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Lipids Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The primary outcome is the proportion of patients overdue who complete lipids screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
DEXA Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete DEXA screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Hemoglobin A1C Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Hemoglobin A1C screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Basic Metabolic Panel Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Basic Metabolic Panel screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
|
Urine Microalbumin Screening Completion (6 months)
Časové okno: Within 6 months after the first eligible primary care visit.
|
The secondary outcome is the proportion of patients overdue who complete Urine Microalbumin screening within 6 months after the first eligible primary care visit.
|
Within 6 months after the first eligible primary care visit.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Shivan Mehta, University of Pennsylvania
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 859571
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .